N4 Pharma PLC Operations Update (1943Z)
20 Mayo 2021 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 1943Z
N4 Pharma PLC
20 May 2021
20 May 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Operations Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide an update on collaboration
discussions and its ongoing in vivo work programme.
Collaborations
The Company is pleased to announce that it has entered into two
Material Transfer Agreements ("MTAs") to assess how well Nuvec(R)
can bind and be optimised for transfection with two different
proprietary plasmids. The first is with a major international
company working in the gene therapy space and the second is a
pharmaceutical company developing its own proprietary vaccine for
Covid-19 using a DNA plasmid. Each MTA is subject to certain
confidentiality clauses as to the extent of detail that may be
disclosed, including the name of the other party. Subject to the
results of the work undertaken these MTAs represent a significant
first step towards more formal collaborations. In addition to the
two MTAs signed, the Company continues in dialogue with other
parties with a view to entering into more MTAs.
In vivo studies
The Company is also pleased to announce it has made good
progress developing and testing a monodisperse formulation of
Nuvec(R). Previous updates have highlighted the success in
preparing monodisperse formulations and recent results from a pilot
in vivo study undertaken by Nanomerics have now indicated that a
lower dose of 10ug pOVA bound to optimised, monodispersed Nuvec(R)
gives a better result than a 50ug dose of the original,
agglomerated Nuvec(R) used in previous in vivo studies. This recent
study will be repeated and extended to validate the results seen
from this pilot study which, if consistent, would demonstrate a
significant improvement through the use of this newly formulated
Nuvec(R) following 18 months of optimisation and formulation
work.
In light of the success with the pilot study, the Company is
reviewing the scope of work at Evotec, which had been announced
previously, to ensure that the different arms to the in vivo
studies undertaken there are complementary and follow the approach
undertaken in the Nanomerics pilot study. Whilst this work remains
ongoing it is likely to push any results from the Evotec in vivo
work into the third quarter of this year. Furthermore, with the
work being undertaken under the MTA in respect of the proprietary
plasmid DNA for Covid-19, the Company now intends to use this
opportunity to assess whether Covid-19 plasmid DNAs other than the
Covid-19 DNA plasmid licensed from the National Institute for
Health may be more suited to its internal Covid-19 in vivo work.
Indeed, depending on the results of the work done under the MTA and
subsequent relationships, it may negate the need for the Company to
do its own proof of concept work with an 'off the shelf' Covid-19
plasmid.
Appointment of an in lab full-time employee
With the additional work from the MTAs and the promising initial
results from the in vivo work, the Company has contracted through
the Medicines Discovery Catapult ("Catapult") access to a full-time
Postdoctoral Researcher , meaning, for the first time, it now has
its own dedicated in lab resource. The Company has been working
with Catapult for some time and their work has been instrumental in
improving and testing Nuvec(R) formulations to this point.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"We are delighted to have entered into two MTAs with these
respected companies, each one addressing different markets. Whilst
there can be no guarantee of either agreement resulting in a
commercial collaboration, it marks a major step forward as we apply
third party materials to Nuvec(R). Furthermore, it validates all
the hard work that has been done in optimising Nuvec(R) that major
players in their fields are prepared to invest their time and
resource to see how Nuvec(R) may be applied to their technologies
and IP.
"In addition, the early data from our in vivo work with the
optimised, monodispersed Nuvec(R) is indicating that we have
significantly improved its functionality and efficacy over the
agglomerated material used in earlier studies. Whilst the results
from the work at Evotec may be a little later than expected, we
remain more optimistic as to the outcome following the results seen
in the pilot study and I look forward to providing further updates
as soon as practicable in the coming months."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre-clinical and clinical programs, N4
Pharma will seek to receive up-front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDALMATMTJBBAB
(END) Dow Jones Newswires
May 20, 2021 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024